ClinicalTrials.gg

Program

raludotatug deruxtecan

Also written as “R-DXd”, “Raludotatug Deruxtecan” and “DS-6000a”.

In Merck’s pipeline, Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi. Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms · Fallopian Tube Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 2 companies.

Furthest: phase 3, since Jul 29, 202611 company-led studies, 11 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck77 open or runningphase 3since Jul 29, 2026Jun 21, 2021Mar 27, 2029phase 2 · NCT06843447
Daiichi Sankyo44 open or runningphase 3since Nov 27, 2023Dec 16, 2020Dec 30, 2026phase 1 · NCT04707248
  • Named in Merck’s own pipeline as raludotatug deruxtecan (MK-5909), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2020First study: phase 1 study in Carcinoma, Renal CellNew to Daiichi SankyoDaiichi Sankyo · NCT04707248 · 179 enrolled · United States, Japan
  2. Jun 21, 2021Merck’s first study: phase 2 study in Small Cell Lung CarcinomaNew to MerckMerck · NCT04938817 · 110 enrolled · United States, Australia, Austria and more
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. Nov 27, 2023Phase 3 study in Ovarian NeoplasmsDaiichi Sankyo · NCT06161025 · 860 planned · United States, Australia, Brazil and more
  5. Oct 25, 2024Phase 2 study in Advanced Solid TumorDaiichi Sankyo · NCT06660654 · 335 enrolled · United States, Belgium, China and more
  6. Jan 13, 20252 phase 2 studiesMerck · NCT06780098, NCT06780085
  7. Feb 20, 2025Phase 2 study in Ovarian Cancer RecurrentMerck · NCT06843447 · 605 planned · United States, Australia, Canada and more
  8. Mar 3, 2025Phase 2 study in Gastrointestinal NeoplasmsMerck · NCT06864169 · 160 enrolled · United States, Argentina, Canada and more
  9. Jul 29, 2026Phase 3 study in Ovarian NeoplasmsPhase 3 reachedMerck · NCT07743164 · 646 planned · United States, China, Israel and more
  10. Aug 3, 2026Phase 3 study in Fallopian Tube NeoplasmsDaiichi Sankyo · NCT07791732 · 600 planned
  11. Aug 17, 2026Phase 3 study in Ovarian NeoplasmsMerck · NCT07776691 · 802 planned · United States, Israel, South Korea and more

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Carcinoma, Renal CellDaiichi Sankyo · NCT04707248
  2. Feb 29, 2028Primary completion: phase 3 study in Ovarian NeoplasmsDaiichi Sankyo · NCT06161025
  3. Mar 27, 2029Primary completion: phase 2 study in Ovarian Cancer RecurrentMerck · NCT06843447
  4. Jul 1, 2029Primary completion: phase 3 study in Fallopian Tube NeoplasmsDaiichi Sankyo · NCT07791732

TargetBeta

“Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) ”NCIt, by rule

Other programs on CDH6

ProgramCompanyFurthest phaseStudies
TJ102rulephrontline-biopharmaphase 21
Anti-CDH6 Antibody-drug Conjugate SIM0505rulenextcure-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07776691Ovarian Neoplasms · United States, Israel, South Korea and more3RecruitingMerckMar 19, 2032802
NCT07791732Fallopian Tube Neoplasms3Not yet recruitingDaiichi SankyoJul 1, 2029600
NCT07743164Ovarian Neoplasms · United States, China, Israel and more3RecruitingMerckAug 31, 2031646
NCT06864169Gastrointestinal Neoplasms · United States, Argentina, Canada and more2Active, not recruitingMerckAug 18, 2026160
NCT06843447Ovarian Cancer Recurrent · United States, Australia, Canada and more2RecruitingMerckMar 27, 2029605
NCT06780098Lung Neoplasms · United States, Chile, China and more2RecruitingMerckMar 2, 2032144
NCT06780085Carcinoma, Non-Small-Cell Lung · United States, Chile, Germany and more2Active, not recruitingMerckMar 12, 203296
NCT06660654Advanced Solid Tumor · United States, Belgium, China and more2Active, not recruitingDaiichi SankyoDec 30, 2029335
NCT06161025Ovarian Neoplasms · United States, Australia, Brazil and more3RecruitingDaiichi SankyoFeb 29, 2028860
NCT04938817Small Cell Lung Carcinoma · United States, Australia, Austria and more2Active, not recruitingMerckDec 10, 2029110
NCT04707248Carcinoma, Renal Cell · United States, Japan1Active, not recruitingDaiichi SankyoDec 30, 2026179

How it is read

Names in the registry

  • “R-DXd”, 5 entries
  • “Raludotatug Deruxtecan”, 2 entries
  • “DS-6000a”, 2 entries
  • “R-DXD”, 1 entry
  • “Raludotatug deruxtecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.